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A B S T R A C T
Non-tuberculous mycobacteria (NTM) are ubiquitous dwellers of environmental niches and are an
established cause of natural and nosocomial infections. The incidence of NTM infections is rising owing to
a growing population of immunocompromised and vulnerable individuals, complex medical and surgical
procedures, as well as increased awareness and diagnostic capabilities. The prevalence of different NTM
varies between continents, regions, and countries. The true global burden of pulmonary and
extrapulmonary disease is unknown and estimates are subject to under and/or over-estimation.
Diagnosis requires confirmation by isolation of NTM along with clinical and radiological criteria, which
may be suboptimal at all levels. Susceptibility testing is complex and clinical breakpoints are not available
for many of the drugs. Frequently, NTM infections are not considered until late in the course of disease.
Improved and rapid detection of tuberculosis cases in high-burden countries has, however, also brought
NTM infections into the limelight, and has identified a need for research efforts towards rapid diagnostic
tests and the identification of biomarkers to monitor the treatment response in patients with NTM
infections.
© 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Non-tuberculous mycobacteria (NTM) are ubiquitous and
widely found in water and soil, as well as residential environments.
Survival in these ecological niches is supported by their ability to
form biofilms (Esteban and Garcia-Coca, 2017). Until recently, NTM
were considered transient colonizers in humans, although their
association with disease is now well recognized and accepted as a
growing problem (Prevots et al., 2017). The rise in NTM infections is
likely to be multifactorial, including a growing cohort of at-risk
populations coupled with perpetually improving diagnostic
capacities.
More than 170 species of NTM are currently recognized, with
the list ever growing (Forbes, 2017). NTM taxonomy is crowded
and complicated, and different species may be more prevalent in
specific geographic settings or milieus (Hoefsloot et al., 2013). NTM
may cause pulmonary (nodular and fibrocavitary disease) as well
as extrapulmonary disease (cutaneous, bone, disseminated), and
frequently affect patients with predisposing conditions, e.g., cystic
fibrosis (CF) and bronchiectasis/chronic obstructive pulmonary
disease (COPD), as well as people living with HIV (Faverio et al.,
2016).
Repeated exposure to environments inhabited by NTM is an
accepted mode of transmission (Honda et al., 2018). Infection is
frequently acquired through inhalation (i.e., aerosol, showers) or
inoculation (trauma, plastic surgery, acupuncture). Outbreaks due
to NTM are also well reported in the literature (Buser et al., 2019;
Lyman et al., 2017).
Defining the problem
The global burden of NTM disease is largely unknown.
Currently, the majority of NTM diseases are not notifiable, notable
exceptions being Mycobacterium chimaera related to cardiac
surgery and heater cooler units and Mycobacterium ulcerans. There
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are several challenges in describing the morbidity and mortality of
NTM disease, its incidence and prevalence, trends, and the
distribution of infections regionally, nationally, or globally.
Moreover, certain countries may be able to enumerate NTM
pulmonary cases through their tuberculosis (TB) programmes, but
these will be an underestimate as they may only be cases de-
notified from TB registries, whereas those not presenting to TB
clinics may not be captured (Shah et al., 2016).
The classification of NTM disease is an integrated clinical–
radiological–microbiological diagnosis, requiring the isolation of
the same species of NTM from two separate sputa (or once only
from bronchoalveolar fluid), evidence of clinical symptoms, and
radiological signs of cavitary or nodular disease on X-ray or
computed tomography (Griffith et al., 2007). Laboratory notifica-
tions on their own are not able to differentiate true disease from
temporary colonization, and other approaches are needed to
capture the full burden of NTM disease.
Given the situation, our current knowledge of NTM disease is
based on fragments of information from different countries,
regions, and multicentre laboratory studies. These suggest that
NTM infections are becoming more prevalent; we do not however
know whether this is due to our rapidly ageing populations,
increasing prevalence of chronic lung diseases, cystic fibrosis
cohorts, immunosuppressed patients, or to improved diagnostic
methods, or most likely, a combination of these.
Diagnostic challenges
A major obstacle in determining the true burden of disease and
identifying patients with NTM infections is limited diagnostic
capacity (both clinical and laboratory) in many low and middle-
income countries. The presentation of NTM pulmonary disease is
usually non-specific, with radiological findings and disease
sequelae being similar to those of TB. Most patients with NTM
disease therefore end up receiving therapy for TB or other common
infections for months or years. Even if the culture report shows
growth of NTM, it may be ignored as a contaminant, and the
patient may not be properly assessed for NTM disease (Varma-
Basil and Bose, 2019). Extrapulmonary infections are frequently
nosocomial: surgical site infections including post-laparoscopic
surgeries, implant infections, central line-associated bloodstream
infections, acupuncture needle-related infections, pedicure-relat-
ed infections, hydrotherapy-associated infections, etc. (Shakoor
et al., 2019). A mycobacterial aetiology is frequently not sought
until the patient has failed the broadest of antibiotic coverage.
When the infection is community-acquired, mycobacteria are
much lower down the list of differentials unless there are
concerted efforts to increase awareness, e.g., in the case of Buruli
ulcer in Japan (Yotsu et al., 2012).
Mycobacterial culture or specific tests should be requested, and
laboratories need to be equipped to identify mycobacteria beyond
Mycobacterium tuberculosis complex (Varma-Basil and Bose, 2019).
NTM are susceptible to harsh decontamination techniques and
thus detection is difficult for fastidious species like Mycobacterium
haemophilum and those NTM requiring incubation at 30 C (e.g.,
Mycobacterium marinum) or 45 C (e.g., Mycobacterium xenopi), as
well as extremely slow-growing species (e.g., M. ulcerans) (Pfyffer,
2015).
The identification techniques, including commercial molecular
systems that can identify clinically relevant mycobacteria, either
directly in samples or from cultured isolates, have their own
limitations: they are technically exacting, costly, and in cases have
low accuracy (Pfyffer, 2015; Quan et al., 2018). Additionally,
susceptibility testing is mostly limited to broth-based methods,
which are difficult to perform and read. Furthermore, due to a
paucity of data, clinical breakpoints for some drug–bug combina-
tions are still not available (Clinical and Laboratory Standards
Institute, 2018). More recently, another avenue being explored for
clinical use is that of genotypic detection of resistance mutations
(Huh et al., 2019).
Most importantly, maintaining tests to identify and report NTM
is not cost-effective, especially where test volumes are low. Few
centres in resource-limited settings therefore invest in such
expertise, resulting in reduced access to reliable diagnostics.
Recognition of NTM as a global concern
According to recent studies, NTM disease is increasing in the
developed world. A recent systematic review analysed 22 studies on
NTM in North America, Europe, Asia, and Australasia reporting this
trend (Brode et al., 2014; van der Werf et al., 2014). NTM lung disease
appearsto be more prevalentwith olderage, whereasNTM disease in
children, HIV-infected patients, and the immunosuppressed is
generally extrapulmonary with a predilection for lymphadenitis.
Disseminated NTM disease is more likely in transplant patients or
patients with a severe primary immunodeficiency, i.e., STAT1
Table 1
Clinical importance of common non-tuberculous mycobacteria (NTM).
NTM species Comments
Mycobacterium avium–intracellulare complex (MAC) Commonly found in most environments and became prominent during the HIV epidemics. Causes
lymphadenitis and lung disease. Prevalence in the HIV population has been reduced dramatically by
ART, but it can affect HIV non-infected people and elderly women (Lady Windermere syndrome).
Mycobacterium kansasii Frequently associated with piped water, likely to affect middle-aged or older men with COPD, and can
cause a pulmonary disease similar to TB.
Mycobacterium abscessus group Frequently pathogenic and very challenging to treat, especially M. abscessus ssp. abscessus, given its
resistance to macrolides; Other subspecies include massiliense and bolletii.
Mycobacterium fortuitum group Not generally considered a pathogen unless nosocomial.
Mycobacterium marinum Relatively rare, but is commonly associated with fish tanks and marine exposure, especially following
skin breaks. Most likely manifestations are skin lesions, which may appear 2–4 weeks after exposure. A
high index of suspicion and knowledge of occupational history and pets is required to make the
diagnosis.
Mycobacterium ulcerans Presents as a chronic skin infection and can be seen in, but is not limited to, Sub-Saharan Africa and the
tropics. It is more prevalent following rains and flooding, frequently following trauma, and affects
children/adolescents, producing painless nodules and ulcers due to the action of a toxin mycolactone.a
Mycobacterium scrofulaceum Generally causes lymphadenitis in children.
Mycobacterium szulgai Commonly reported as a cause of pulmonary disease and as complicating infection in post-TB patients.
Mycobacterium simiae Does not always represent disease, but when it does, it can be very challenging to manage as it generally
does not respond to treatment.
ART, antiretroviral therapy; COPD, chronic obstructive pulmonary disease; TB, tuberculosis.
a Reference: Sarfo et al., 2016.
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deficiency, interferon-gamma receptor deficit, or recipients of anti-
tumour necrosis factor alpha (anti-TNF-α). CF patients are likely to be
colonized with NTM and may develop NTM disease. NTM can cause
rapidly progressing fibrocavitary pulmonary disease or disseminat-
ed disease in the immunocompromised. Localized manifestations
may be skin and soft tissue infection from direct inoculation and
lymphadenitis, typically cervical. Table 1 shows the niches and
importance of some common NTM species seen in clinical practice.
NTM have recently been found to be putative causes of
iatrogenic infections and outbreaks, and are now established as
nosocomial pathogens (Desai and Hurtado, 2018). Outbreaks in CF
patients have occurred, demonstrating the role of the environment
in colonizing and infecting predisposed individuals (Martiniano
et al., 2017), and these human-to-human transmission events have
been proven as possible through whole genome sequencing
(Bryant et al., 2013; Kapnadak et al., 2016). Therefore, efforts
must be made to protect CF patients from the hospital environ-
ment, as well as to reduce the potential of spread of frequently
drug-resistant nosocomial strains amongst patients; these include
thorough cleaning between patients, environmental sampling,
negative pressure rooms, and HEPA filters and UV lamps in
outpatient spaces (Shakoor et al., 2019). Recently, the contamina-
tion of heater–cooler units produced by a specific manufacturer
was implicated in a global outbreak of M. chimaera in post heart
valve surgery patients, causing surgical site infections and/or
endocarditis, characterized by high mortality rates. New models of
the machines have rectified the problem; however, the infection
can remain latent for many years. It is difficult to diagnose and
treat, and therefore the extent of the problem is likely to be
underestimated (Hasse et al., 2020; Scriven et al., 2018).
NTM as an emerging problem in Pakistan, a high TB burden
country
Rapid diagnostics have not only improved TB detection, but the
massive roll-out of Xpert MT/RIF in high-burden countries has also
unmasked NTM infections masquerading as acid-fast bacillus
(AFB) smear-positive TB that has failed to respond to several
courses of anti-tubercular therapy: treatment failure or reactiva-
tion (Javaid et al., 2016; Tahseen et al., 2016; Velayati et al., 2015).
Data from the mycobacteriology section of the clinical
laboratories of Aga Khan University (AKU), which is also the
Figure 1. Distribution of the common groups of non-tuberculous mycobacteria (NTM) isolated from pulmonary and extrapulmonary samples with NTM infections over the
period 2012 to 2018, from the Microbiology Laboratory of Aga Khan University Hospital, Karachi, Pakistan.
Note: MAC, Mycobacterium avium–intracellulare complex; MK, Mycobacterium kansasii; SGM, slow-growing mycobacteria; MACG, Mycobacterium abscessus–chelonae group;
MFG, Mycobacterium fortuitum group; RGM, rapidly growing mycobacteria; M. spp., Mycobacterium species; P, pulmonary infections; EP, extrapulmonary infections.
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supranational reference TB laboratory, were analysed. The
laboratory, situated in Karachi, receives specimens from most
parts of the country through a network of specimen collection
units; however, the data only represent a single laboratory
experience from Pakistan. These showed a 7.7-fold increase in
NTM infections, from 21 cases in 2012 to 163 in 2018 (Figure 1). The
greatest increase in numbers was seen in pulmonary disease,
contributing to 89.6% of the NTM cases, with most patients having
a prior history of TB and evidence of bronchiectasis and fibrocystic
changes in their lungs.
Extrapulmonary NTM infections are less common, but are
increasingly recognized as important agents of nosocomial
infections. Reports from Pakistan have already been published
and a review of laboratory data from AKU revealed that 42% of
extrapulmonary NTM infections were post-surgical, after caesare-
an section, laparoscopic surgeries, orthopaedic surgeries with and
without implants, and mastectomies. The rates of these procedures
are increasing in both the private and public sectors of developing
countries like Pakistan, but the accompanying infection prevention
strategies both during and after surgery are woefully inadequate
(Shakoor et al., 2019). With a low index of suspicion and limited
access to proper laboratory diagnosis, this documented rate of
nosocomial NTM infections may very likely be an underestimate of
the real situation.
As expected, with such different predisposing factors, the
spectrum of NTM species causing pulmonary and extrapulmonary
infections also differs. In our setting, a predominance of slow-
growing mycobacteria, Mycobacterium avium–intracellulare com-
plex (MAC) and Mycobacterium kansasii, was common in the group
with pulmonary infections, but not in those with extrapulmonary
disease. Rapidly growing mycobacteria (RGM), primarily from
Mycobacterium chelonae/Mycobacterium abscessus group (MCAG)
and Mycobacterium fortuitum group (MFG), while seen in both
pulmonary and extrapulmonary infections, were associated with
more than 80% of extrapulmonary NTM infections.
An earlier study evaluating the distribution of NTM species
across Pakistan suggested geographical variation across different
regions, every area having its own distribution spectrum (Ahmed
et al., 2013). The differences were especially discernible between
urban centres where access to bronchoscopy and more in-depth
diagnostic efforts contribute to the detection of a larger number of
NTM cases. The study further suggested clarithromycin as the
mainstay of therapy for NTM infections in both slow-growing
(SGM) and rapidly growing (RGM), with linezolid as a good
alternative. Resistance to fluoroquinolones was, however, preva-
lent. Among injectable drugs, most RGMs were susceptible to
amikacin, while limited imipenem activity was reported on
isolates from Pakistan (Ahmed et al., 2013). The susceptibility
profile suggested the use of antimicrobials in the area, nosocomial
isolates being more resistant to injectables, but community-
acquired isolates showing higher resistance to commonly used oral
agents like fluoroquinolones.
Future directions
A low level of suspicion, limited knowledge, and paucity of
specialized laboratories frequently lead to diagnostic delays. The
median time to diagnosis may be as high as 2 years or longer. The
delay frequently results in increased disease severity, and loss of
functional capacity is not infrequent. The advent of molecular
testing for TB is a surrogate test that allows the diagnosis of NTM
through deduction in the case of AFB-positive, TB PCR-negative
results. MALDI-TOF MS (matrix-assisted laser desorption/ioniza-
tion time-of-flight mass spectrometry) and sequencing has further
reduced the time to diagnosis of NTM infections and has improved
our capacity for speciation. These new techniques enable outbreak
investigations to be performed with some certainty. Phenotypic
sensitivities are important, especially in patients who have
received macrolides as monotherapy for infective exacerbation
of COPD or who have relapsed or non-responsive disease.
Differentiating colonization from disease often requires more
than one outpatient visit and several sputum samples or a
bronchoscopy to isolate mycobacteria. In patients with a co-
existing lung pathology, the NTM may be a relatively innocent
bystander or be a co-infection in synergy with Aspergillus spp. or
Pseudomonas aeruginosa (Geurts et al., 2019).
Simpler and more rapid tests would be ideal in making the
diagnosis of NTM disease more quickly. However, the develop-
ment of such tests is complicated by the large number of NTM
species that can cause disease and by the criteria for disease,
which require more than just the presence of the microorganism.
As a result, NTM disease will require multiple diagnostic
parameters, leading to delays and higher costs. More specific
biomarkers to monitor the progress of treatment and test cure are
lacking. The treatment of NTM remains lengthy, in many cases 18
months with a minimum 12 months after culture conversion in
lung disease. In the future, more effective therapies, biomarkers,
and/or imaging may help reduce the duration of treatment in a
precise way.
Ethical approval
Not required.
Conflict of interest
None to declare.
Acknowledgements
This project is part of the activities of the Global Tuberculosis
Network (GTN) and of the WHO Collaborating Centre for
Tuberculosis and Lung Diseases, Tradate, ITA-80, 2017-2020-
GBM/RC/LDA. This article is part of a supplement entitled
Commemorating World Tuberculosis Day March 24th, 2020: “IT’S
TIME TO FIND, TREAT ALL and END TUBERCULOSIS!” published with
support from an unrestricted educational grant from QIAGEN
Sciences Inc.
References
Ahmed I, Jabeen K, Hasan R. Identification of non-tuberculous mycobacteria isolated
from clinical specimens at a tertiary care hospital: a cross-sectional study. BMC
Infect Dis 2013;13:493.
Brode SK, Daley CL, Marras TK. The epidemiologic relationship between tuberculosis
and non-tuberculousmycobacterialdisease:a systematic review. Int J Tuberc Lung
Dis 2014;18(11):1370–7.
Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I, Inns T, et al. Whole-
genome sequencing to identify transmission of Mycobacterium abscessus
between patients with cystic fibrosis: a retrospective cohort study. Lancet
2013;381(9877):1551–60.
Buser GL, Laidler MR, Cassidy PM, Moulton-Meissner H, Beldavs ZG, Cieslak PR.
Outbreak of nontuberculous mycobacteria joint prosthesis infections, Oregon,
USA, 2010-2016. Emerg Infect Dis 2019;25(5):849–55.
Clinical and Laboratory Standards Institute. Performance standards for susceptibil-
ity testing of mycobacteria, nocardia, and other aerobic actinomycetes. M62. 1st
ed. Clinical and Laboratory Standards Institute; 2018.
Desai AN, Hurtado RM. Infections and outbreaks of nontuberculous mycobacteria in
hospital settings. Curr Treat Options Infect Dis 2018;10(2):169–81.
Esteban J, Garcia-Coca M. Mycobacterium biofilms. Front Microbiol 2017;8:2651.
Faverio P, Stainer A, Bonaiti G, Zucchetti SC, Simonetta E, Lapadula G, et al.
Characterizing non-tuberculous mycobacteria infection in bronchiectasis. Int J
Mol Sci 2016;17(11).
Forbes BA. Mycobacterial taxonomy. J Clin Microbiol 2017;55(2):380–3.
Geurts K, Zweijpfenning SMH, Pennings LJ, Schildkraut JA, Boeree MJ, Magis-Escurra
C, et al. Nontuberculous mycobacterial pulmonary disease and aspergillus co-
infection: Bonnie and Clyde?. Eur Respir J 2019;54(1).
I. Ahmed et al. / International Journal of Infectious Diseases 92S (2020) S46–S50 S49
Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official
ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous
mycobacterial diseases. Am J Respir Crit Care Med 2007;175(4):367–416.
Hasse B, Hannan M, Keller PM, Maurer FP, Sommerstein R, Mertz D, et al.
International society of cardiovascular infectious diseases guidelines for the
diagnosis, treatment and prevention of disseminated Mycobacterium chimaera
infection following cardiac surgery with cardiopulmonary bypass. J Hosp Infect
2020;104(2):214–35.
Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, et al. The
geographic diversity of nontuberculous mycobacteria isolated from pulmonary
samples: an NTM-NET collaborative study. Eur Respir J 2013;42(6):1604–13.
Honda JR, Virdi R, Chan ED. Global environmental nontuberculous mycobacteria and
theircontemporaneousman-madeandnaturalniches.FrontMicrobiol2018;9:2029.
Huh HJ, Kim SY, Shim HJ, Kim DH, Yoo IY, Kang OK, et al. GenoType NTM-DR
performance evaluation for identification of Mycobacterium avium complex and
Mycobacterium abscessus and determination of clarithromycin and amikacin
resistance. J Clin Microbiol 2019;57(8).
Javaid M, Ahmed A, Asif S, Raza A. Diagnostic plausibility of MTBDRplus and
MTBDRsl line probe assays for rapid drug susceptibility testing of drug resistant
Mycobacterium tuberculosis strains in Pakistan. Int J Infect 2016;3(3)e34903.
Kapnadak SG, Hisert KB, Pottinger PS, Limaye AP, Aitken ML. Infection control
strategies that successfully controlled an outbreak of Mycobacterium abscessus
at a cystic fibrosis center. Am J Infect Control 2016;44(2):154–9.
Lyman MM, Grigg C, Kinsey CB, Keckler MS, Moulton-Meissner H, Cooper E, et al.
Invasive nontuberculous mycobacterial infections among cardiothoracic
surgical patients exposed to heater-cooler devices(1). Emerg Infect Dis
2017;23(5):796–805.
Martiniano SL, Davidson RM, Nick JA. Nontuberculous mycobacteria in cystic
fibrosis: updates and the path forward. Pediatr Pulmonol 2017;52(S48):S29–36.
Pfyffer GE. Mycobacterium: general characteristics, laboratory detection, and
staining procedures. In: Jorgensen JH, Pfaller MA, Carroll KC, Funke G, Landry
ML, Richter SS, Warnock DW, editors. Manual of clinical microbiology. 11 ed.
Washington, DC: ASM Press; 2015.
Prevots DR, Loddenkemper R, Sotgiu G, Migliori GB. Nontuberculous mycobacterial
pulmonary disease: an increasing burden with substantial costs. Eur Respir J
2017;49(4).
Quan TP, Bawa Z, Foster D, Walker T, Del Ojo Elias C, Rathod P, et al. Evaluation of
whole-genome sequencing for mycobacterial species identification and drug
susceptibility testing in a clinical setting: a large-scale prospective assessment
of performance against line probe assays and phenotyping. J Clin Microbiol
2018;56(2).
Sarfo FS, Phillips R, Wansbrough-Jones M, Simmonds RE. Recent advances: role of
mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans
infection/Buruli ulcer disease. Cell Microbiol 2016;18(1):17–29.
Scriven JE, Scobie A, Verlander NQ, Houston A, Collyns T, Cajic V, et al.
Mycobacterium chimaera infection following cardiac surgery in the United
Kingdom: clinical features and outcome of the first 30 cases. Clin Microbiol
Infect 2018;24(11):1164–70.
Shah NM, Davidson JA, Anderson LF, Lalor MK, Kim J, Thomas HL, et al. Pulmonary
Mycobacterium avium-intracellulare is the main driver of the rise in non-
tuberculous mycobacteria incidence in England, Wales and Northern Ireland,
2007-2012. BMC Infect Dis 2016;16:195.
Shakoor S, Owais M, Hasan R, Irfan Seema. Nosocomial and healthcare-associated
NTM infections and their control. In: Velayati AA, Farnia P, editors. Non-
tuberculous mycobacteria (NTM) microbiological, clinical and geographical
distribution. Elsevier Inc.; 2019. p. 177–90.
Tahseen S, Qadeer E, Khanzada FM, Rizvi AH, Dean A, Van Deun A, et al. Use of Xpert
((R)) MTB/RIF assay in the first national anti-tuberculosis drug resistance survey
in Pakistan. Int J Tuberc Lung Dis 2016;20(4):448–55.
van der Werf MJ, Kodmon C, Katalinic-Jankovic V, Kummik T, Soini H, Richter E, et al.
Inventory study of non-tuberculous mycobacteria in the European Union. BMC
Infect Dis 2014;14:62.
Varma-Basil M, Bose M. Mapping the footprints of nontuberculous mycobacteria: a
diagnostic dilemma. In: Velayati AA, Farina P, editors. Nontuberculous
mycobacteria (NTM) microbiological, clinical and geographical distribution. .
p. 155–75.
Velayati AA, Rahideh S, Nezhad ZD, Farnia P, Mirsaeidi M. Nontuberculous
mycobacteria in Middle East: current situation and future challenges. Int J
Mycobacteriol 2015;4(1):7–17.
Yotsu RR, Nakanaga K, Hoshino Y, Suzuki K, Ishii N. Buruli ulcer and current situation
in Japan: a new emerging cutaneous Mycobacterium infection. J Dermatol
2012;39(7):587–93.
S50 I. Ahmed et al. / International Journal of Infectious Diseases 92S (2020) S46–S50
